

[ PICTURES IN CLINICAL MEDICINE ]

## Post-COVID-19 Postural Orthostatic Tachycardia Syndrome


Yuki Ishibashi<sup>1</sup>, Kihei Yoneyama<sup>1</sup>, Tomoya Tsuchida<sup>2</sup> and Yoshihiro J. Akashi<sup>1</sup>

**Key words:** postural orthostatic tachycardia syndrome, tilt test, COVID-19


(Intern Med 60: 2345, 2021)

(DOI: 10.2169/internalmedicine.7626-21)

### A. No medication



### B. Two-week after taking 2.5 mg of bisoprolol



**Picture.**

We herein report a 25-year-old woman who developed new-onset postural orthostatic tachycardia syndrome (POTS) following COVID-19 infection without pneumonia. Three weeks after being diagnosed with COVID-19, she began experiencing fatigue, feeling unwell, intermittent palpitation, dyspnea and chest pain, especially while getting up from the sitting position. Her tilt test showed an increase in her heart rate from 80 bpm in the supine position to 110 bpm in the absence of hypotension during a 10-minute head-up tilt at an angle of 90°, which returned to the baseline level immediately after lowering to the supine position (Picture A). These measurements fit the criteria of POTS. Of note, her

heart rate temporarily decreased after lower limb counter-maneuvers were performed (Picture A). We have found low-dose bisoprolol (2.5 mg oral, daily) to be markedly effective in reducing the standing heart rate and improving symptoms acutely (Picture B).

**The authors state that they have no Conflict of Interest (COI).**

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

<sup>1</sup>Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan and <sup>2</sup>Division of General Internal Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Japan

Received: March 24, 2021; Accepted: April 16, 2021; Advance Publication by J-STAGE: May 29, 2021

Correspondence to Dr. Yuki Ishibashi, [ishibashi15@marianna-u.ac.jp](mailto:ishibashi15@marianna-u.ac.jp)

© 2021 The Japanese Society of Internal Medicine. *Intern Med* 60: 2345, 2021